Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, Ritz J, Nikiforow S. Murad JM, et al. Among authors: gilham d. Cytotherapy. 2018 Jul;20(7):952-963. doi: 10.1016/j.jcyt.2018.05.001. Epub 2018 Jun 29. Cytotherapy. 2018. PMID: 30180944 Free PMC article.
Exploiting natural killer group 2D receptors for CAR T-cell therapy.
Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Demoulin B, et al. Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14. Future Oncol. 2017. PMID: 28613086 Free article. Review.
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Baumeister SH, et al. Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5. Cancer Immunol Res. 2019. PMID: 30396908 Free PMC article. Clinical Trial.
Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.
Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF. Lonez C, et al. BMJ Open. 2017 Nov 12;7(11):e017075. doi: 10.1136/bmjopen-2017-017075. BMJ Open. 2017. PMID: 29133316 Free PMC article. Clinical Trial.
Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF. Lonez C, et al. Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4. Curr Res Transl Med. 2018. PMID: 29625833 Review.
Overcoming Target Driven Fratricide for T Cell Therapy.
Breman E, Demoulin B, Agaugué S, Mauën S, Michaux A, Springuel L, Houssa J, Huberty F, Jacques-Hespel C, Marchand C, Marijsse J, Nguyen T, Ramelot N, Violle B, Daro D, De Waele P, Gilham DE, Steenwinckel V. Breman E, et al. Among authors: gilham de. Front Immunol. 2018 Dec 12;9:2940. doi: 10.3389/fimmu.2018.02940. eCollection 2018. Front Immunol. 2018. PMID: 30619300 Free PMC article.
111 results